Dr. Ido Weinberg

Dr. Weinberg is the founder and Editor In-Chief of Angiologist.com. He is a Vascular Medicine physician at Hadassah Hebrew University Medical Center, Associate Professor of Medicine at Harvard Medical School and Past President of the Society for Vascular Medicine.

anti Xa

Anti Xa is a measure for the activity of anticoagulation. The name of the assay is confusing. It is a measure for the activity of heparin or or low molecular weight heparin. Chromogenic Xa is a measure of the activity of coumadin. It is used when starting warfarin during treatment with argatroban. What is Anti…

Read More

Inferior Vena Cava Thrombosis

Inferior vena cava thrombosis is usually the result of an IVC filter. However, native IVC thrombosis is also encountered. While it is a form of deep vein thrombosis, the natural history of IVC thrombosis is variable. It ranges from remaining asymptomatic for the long-term to debilitating bilateral leg swelling. Diagnosis The diagnosis of IVC thrombosis…

Read More

Foot care

This is an Angiologist.com patient handout about foot care. Angiologist.com patient handouts are not medical advice. They are intended as a general guide. For specific instructions please contact your doctor. Why is foot care important? The simplest of foot injuries can be terrible for people who have vascular problems. Even a small ulcer, cut or…

Read More

Dabigatran

Dabigatran (marketed as Pradaxa in the United States) is an oral direct thrombin inhibitor. It is FDA approved for use for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation at a dose of 150 mg BID. This approval is based mainly on the RE-LY trial. Dabigatran will also be approved…

Read More

VTE Treatment Duration

How long should a clot be treated for? This question is central to the care of patients with venous thromboembolism (deep vein thrombosis and pulmonary embolism). The way to decide, is to balance potential benefits and risks of shorter and longer treatment durations. Put simply, VTE treatment duration balances risk of recurrence, risk of bleeding…

Read More

Managing Anticoagulation and Thrombocytopenia

Managing anticoagulation and thrombocytopenia is challenging. The obvious risk is bleeding. Anticoagulation and thrombocytopenia are therefore a combination that mandates particular attention. Specifically two questions need to be asked: What is the risk for thrombosis in patients with thrombocytopenia? What is the lowest platelet count in which anticoagulation may still be given in the setting…

Read More
Vascular Medicine